<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626375</url>
  </required_header>
  <id_info>
    <org_study_id>BIOARGININA</org_study_id>
    <nct_id>NCT04626375</nct_id>
  </id_info>
  <brief_title>Effects of L-arginine on Myocardial Energetic Efficiency and Global Longitudinal Strain</brief_title>
  <acronym>BIOCARDIO</acronym>
  <official_title>Effects of L-arginine on Myocardial Energetic Efficiency and Global Longitudinal Strain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Raffaele Izzo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prof. Costantino Mancusi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the effects of L-arginine on myocardial structure and&#xD;
      function and circulating microRNAs in patients with arterial hypertension.&#xD;
&#xD;
      The study will analyze the impact of 4 weeks treatment randomized to L-arginine or placebo,&#xD;
      on mechanical-energy efficiency (MEE) and longitudinal strain in patients with arterial&#xD;
      hypertension. The investigators will also assess whether the changes in MEE and strain&#xD;
      induced by L-arginine treatment is associated with changes in circulating micro RNAs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients and controls will be recruited at the Hypertension research center of Federico&#xD;
      II university hospital.&#xD;
&#xD;
      The overall duration of the study will be 4 weeks for each participant. Blood pressure, heart&#xD;
      rate, echocardiogram and blood sample will be collected for each patients at randomization&#xD;
      and after 4 weeks of treatment.&#xD;
&#xD;
      Patients or controls will be randomized to receive bioarginine (up to 2 vials per os of 1.66&#xD;
      g every 12 hours) or placebo (up to 2 vials per os without active substance every 12 hours).&#xD;
      Before the start of treatment, patients will receive a peripheral venous blood sample (10-12&#xD;
      ml), which will be identified through the use of an alphanumeric code (PRE-XXXYYY). In&#xD;
      addition, patients will undergo full echocardiographic examination (the parameters will be&#xD;
      reported in a password-protected database, using the same identification codes used for blood&#xD;
      sampling). The duration of the treatment will be 4 weeks. At the end of the treatment, the&#xD;
      patients will receive a peripheral venous blood sample (10-12 ml) which will be identified&#xD;
      through the use of an alphanumeric code (POST-XXXYYY) and full echocardiographic examination.&#xD;
&#xD;
      In some controls, we will run an explorative study to verify the eventual impact of&#xD;
      Bioarginine on standardized physical exercise. Healthy controls will undergo a physical&#xD;
      exercise according to their preference, at baseline and after 4 weeks of treatment or&#xD;
      placebo. Ear lobe blood samples are taken before and after the effort and analyzed for serum&#xD;
      lactate content using the reflectance photometric enzymatic reaction method. All L-arginine&#xD;
      and placebo, made up of the L-arginine vehicle without the active substance, will be offered&#xD;
      free of charge by the Farmaceutici DAMOR company.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Myocardial Energetic Efficiency</measure>
    <time_frame>4 week</time_frame>
    <description>Myocardial Energetic Efficiency is calculated as SV/HR/60/LV mass measuring the amount of blood pumped by left ventricle each second per each gram of left ventricular mass</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in global longitudinal strain</measure>
    <time_frame>4 week</time_frame>
    <description>Global longitudinal strain represent the longitudinal shortening as a percentage (change in length as a proportion to baseline length) (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variation of circulating non-coding RNA</measure>
    <time_frame>4 week</time_frame>
    <description>Variation of circulating non-coding RNA is evaluated by blood samples of venous blood and expressed as fold change to placebo patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myocardial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (2 vials per os without active substance every 12 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bioarginine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bioarginine (2 vials per os of 1.66 g every 12 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bioarginine</intervention_name>
    <description>In the Bioarginine group the partecipants take bioarginine (2 vials per os of 1.66 g every 12 hours) for 4 week</description>
    <arm_group_label>Bioarginine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>In the Placebo group the participants take bio-arginine (2 vials per os of 1.66 g every 12 hours) for 4 week</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Low values of mechanical-energy efficiency&#xD;
&#xD;
          -  Sinus rhytm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Taking Beta blockers&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Trimarco, MF</last_name>
    <role>Study Director</role>
    <affiliation>Federico II University, DPT of Advanced Biomedical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruno Trimarco, MD</last_name>
    <phone>+390817462250</phone>
    <email>trimarco@unina.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raffaele Izzo, MD</last_name>
    <phone>+390817462211</phone>
    <email>raffaele.izzo@unina.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ambulatorio Ipertensione e Unità Coronarica Federico II University</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Izzo, MD, PhD</last_name>
      <phone>+390817462211</phone>
      <email>rafizzo@unina.it</email>
    </contact>
    <contact_backup>
      <last_name>Costantino Mancusi, MD</last_name>
      <phone>+390817462211</phone>
      <email>costantino.mancusi@unina.it</email>
    </contact_backup>
    <investigator>
      <last_name>Raffaele Izzo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Shah AM, Solomon SD. Myocardial deformation imaging: current status and future directions. Circulation. 2012 Jan 17;125(2):e244-8. doi: 10.1161/CIRCULATIONAHA.111.086348. Review. Erratum in: Circulation. 2013 Mar 5;127(9):e479.</citation>
    <PMID>22249531</PMID>
  </results_reference>
  <results_reference>
    <citation>Karlsen S, Dahlslett T, Grenne B, Sjøli B, Smiseth O, Edvardsen T, Brunvand H. Global longitudinal strain is a more reproducible measure of left ventricular function than ejection fraction regardless of echocardiographic training. Cardiovasc Ultrasound. 2019 Sep 2;17(1):18. doi: 10.1186/s12947-019-0168-9.</citation>
    <PMID>31477137</PMID>
  </results_reference>
  <results_reference>
    <citation>Tschöpe C, Senni M. Usefulness and clinical relevance of left ventricular global longitudinal systolic strain in patients with heart failure with preserved ejection fraction. Heart Fail Rev. 2020 Jan;25(1):67-73. doi: 10.1007/s10741-019-09853-7. Review.</citation>
    <PMID>31489515</PMID>
  </results_reference>
  <results_reference>
    <citation>Bianco CM, Farjo PD, Ghaffar YA, Sengupta PP. Myocardial Mechanics in Patients With Normal LVEF and Diastolic Dysfunction. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):258-271. doi: 10.1016/j.jcmg.2018.12.035. Epub 2019 Jun 12. Review.</citation>
    <PMID>31202770</PMID>
  </results_reference>
  <results_reference>
    <citation>Nahum J, Bensaid A, Dussault C, Macron L, Clémence D, Bouhemad B, Monin JL, Rande JL, Gueret P, Lim P. Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients. Circ Cardiovasc Imaging. 2010 May;3(3):249-56. doi: 10.1161/CIRCIMAGING.109.910893. Epub 2010 Mar 16.</citation>
    <PMID>20233858</PMID>
  </results_reference>
  <results_reference>
    <citation>Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart. 2014 Nov;100(21):1673-80. doi: 10.1136/heartjnl-2014-305538. Epub 2014 May 23. Review.</citation>
    <PMID>24860005</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Bruno Trimarco</investigator_full_name>
    <investigator_title>Full Professor</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Echocardiography</keyword>
  <keyword>Global Longitudinal Strain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sprains and Strains</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

